Menu
Eisai and PAI Pharma notified covered entities of the refunds and NDC changes in announcements posted to the Health Resources and Services Administration’s Office of Pharmacy Affairs website.

Eisai Announces 340B Refunds, PAI Pharma Issues New Drug Codes 

Luke Zarzecki, National Correspondent 340B Report Views
A Japanese drugmaker recently announced 340B refunds for covered entities that purchased an anti-seizure medication in 2023, while a South [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Webinar–The 340B Rebate Model Discussion Returns: HRSA Sends Proposal to the White House

Three Drugmakers Exempt New States from Contract Pharmacy, Claims Data Policies

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live